Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #27 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Granules India Limited (this stock) | 20,251 | 49.5 | 11.7% | 47.9% | — | 73 | 40 | 32 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 1,477 | 240 | 180 | ₹ |
| March 31, 2026 | 1,471 | 262 | 202 | ₹ |
| Dec. 31, 2025 | 1,388 | 202 | 150 | ₹ |
| Sept. 30, 2025 | 1,297 | 176 | 131 | ₹ |
| June 30, 2025 | 1,210 | 145 | 113 | ₹ |
| March 31, 2025 | 1,197 | 198 | 152 | ₹ |
| Dec. 31, 2024 | 1,138 | 153 | 118 | ₹ |
| Sept. 30, 2024 | 967 | 128 | 97 | ₹ |
| June 30, 2024 | 1,180 | 181 | 135 | ₹ |
| March 31, 2024 | 1,176 | 176 | 130 | ₹ |
| Dec. 31, 2023 | 1,156 | 170 | 126 | ₹ |
| Sept. 30, 2023 | 1,189 | 136 | 102 | ₹ |
| June 30, 2023 | 986 | 65 | 48 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 5,366 | 785 | 595 |
| March 31, 2025 | 4,482 | 660 | 502 |
| March 31, 2024 | 4,506 | 547 | 405 |
| March 31, 2023 | 4,512 | 687 | 517 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 793 | -773 | 379 | 558 | 235 |
| March 31, 2025 | 867 | -691 | -93 | 572 | 295 |
| March 31, 2024 | 439 | -360 | 8 | 381 | 59 |
| March 31, 2023 | 739 | -191 | -440 | 411 | 328 |
| March 31, 2022 | 332 | -380 | 190 | 398 | -66 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 7,720 | 5,085 | 5,060 | 1,041 | 297 | 3,768 | 2,092 | 880 | 3,051 | 1,673 |
| March 31, 2025 | 6,253 | 3,716 | 3,691 | 974 | 312 | 3,115 | 2,003 | 466 | 2,217 | 1,343 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
